Naomi Osaka showed that she is on the strategy to recovering the abdominal injury, which she forced the Australian Open in January, but sharp and Match Tough will take somewhat more time.

Osaka, the four-time Grand Slam champion and former world No. 1, lost in the primary round of the Indian Wells against Camila Osorio from Colombia, the world No. 53, in straight sentences (6-4, 6-4). On social media, she later described the defeat because the “worst match that I have ever played in my life”.

Osaka, the 56th place, and Osorio were even dead in the primary eight games, but Osaka committed a flood of mistakes at 4: 4. There was the chance to serve the set, and the spun Colombian didn’t waste it.

The game was a microcosm of the sport. Osaka has made mistakes in every respect. Balls flew long and wide. Some missing by a number of centimeters. Others miss a number of meters.

The mistakes were particularly widespread when Osaka was under pressure. Osaka and Patrick Mouratoglou, their trainer since September, focused on this dynamic for months and appeared to be a job when Osaka got on the way in which at the start of the 12 months.

Osaka scored the ultimate in Auckland and rolled against Clara Tauson when she worsened a belly injury and retired after the primary sentence. Osaka played a few of her best tennis since her return from maternity leave in early 2024 to 2 1/2 games on the Australian Open, including one victory against Karolina Muchova, among the best players on this planet.

Then Osaka burdened the muscle again and, after the primary set, needed to withdraw from her game within the third round with Belinda Bencic. She had dominated Bencic to the injury.

Osaka returned to California and rested. But she had two hard weeks of coaching in front of Indian wells, and Mouratoglou said she was able to go. Maybe the tennis is probably not there.

“It's crazy for me, a dream comes true,” said 23 -year -old Osorio, who had never won a match in Indian fountain. Her victory was the primary time that a girl from Colombia hit a former world No. 1.

For Osaka, who won Indian Wells in 2018, it enables her to rest before going to Miami Open, one among the events that keep her heart closest and near her event that grew up in Südflorida. After her defeat, Osaka confirmed that her body was fit, but her shape was simply not there.

“I don't think I was too good at my end,” she said in her press conference.

She described a frustrating month after the Australian Open, through which she was not allowed to play for per week and was then allowed to serve slowly, but provided that she slowly increased her intensity from week to week in order not to alleviate her abdominal muscle.

“I did well in Australia,” she said. “It feels a bit like starting again.”

Despite the loss, Osaka said that her begin to the 12 months was much better than last 12 months when she tried to search out a consistency. Or perhaps she gets used to the concept that she’s going to probably never take a smooth journey to the highest of the game.

“It feels like a bump on the street,” she said. “I don't have the feeling that I played well at all, but I still have the feeling that I had so many chances of being involved.”

Required reading

The latest within the healthcare system Tech: AI is the main focus of the HIMSS conference in Vegas starts

By Noah Wchung

Dihydrotestosterone or DHT is an androgen hormone produced by testosterone. High values ​​of Dht Can cause hair loss problems, including androgenetic alopecia or aga, and male sample, SAVEHEATHETH Reports.

Prescription DHT shampoos comparable to Ketoconazole reduce DHT production by locally geared toward the hormone cycle on latest hair growth fames.

Over-the-counter DHT-Shampoos aim to lower the DHT levels, and sometimes natural products that may reduce DHT, including SAW palmetto and pumpkin seed oil. These shampoos may also use other hair -impaired ingredients comparable to biotin, keratin and caffeine.

Studies show that prescription DHT shampoos are effective within the treatment of hair loss, especially together with other hair loss treatments. There are only limited studies on natural DHT low products.

The unwanted effects of DHT shampoos are generally mild. You can include skin problems comparable to itchy and dry skin.

People who are suffering from hair loss brought on by androgenetic alopecia or telogen -fleuvium can find DHT useful of their treatment program, especially in the sooner stages of hair loss, since DHT shampoos cannot reverse hair loss. Men who take 5-alpha reductase inhibitors or other hormonal hair loss medications can use DHT shampoos as a part of their combination treatment.

What is DHT and the way does it cause hair loss?

Dihydrotestosterone is a hormone. In particular, it’s a sex steroid that’s produced within the gonades. It plays as a “androgen” hormone An necessary a part of the male biological properties Like muscle mass, the event of body hair and the depth of the voice. DHT is generated in men when an enzyme called 5-alpha reductase or 5-AR Testosterone within the prostate and the testicles converts into DHT. DHT adheres to the identical places as testosterone, but is an extended time period. DHT's role in hair growth is complicated. It is believed that DHT is attached to hair follicles by androgen receptors, and it’s needed for many hair growth. Axis hair, pubic hair and other body hair don’t grow without DHT. However, it has a negative impact on headhair growth. For unknown reasons, a high level of DHT hair loss and thinning triggers. It may be a very important consider Androgenetic alopeciaAlso known as male model, although AGA is experienced by each men and ladies. Bald male patternOr AGA is probably the most common reason behind male hair loss. Hair loss may be very common in men and affects almost half of all men over 50 years. Almost 50 million men and about 30 million women within the United States suffer from AGA.

How do prescription DHT shampoos work?

Since high androgen hormones may cause hair loss, prescription DHT shampoos comparable to ketoconazole are “anti-and-rogeetical”. She prevent the formation of the androgenetic hormone -dhtin addition to the formation of testosterone that’s converted into DHT. The shampoo goals at these hormones on site at the positioning of recent growth hair follicles. The aim is to disturb the hormone cycle that causes thinning and baldness.

What other sorts of DHT shampoos are there?

Many over-the-counter hair loss shampoos also aim at DHT and sometimes use natural ingredients which have shown promising when reducing the DHT values. Frequent natural ingredients utilized in over-the-counter DHT shampoos saw palmettoPygeum Bark and Pumpkin oil. Many of those over-the-counter hair loss shampoos may also produce other ingredients which might be assumed to revive and promote hair growth comparable to biotin, caffeine, keratin and rosemary oil.

Do you’re employed DHT shampoos?

Only limited studies on shampoos were carried out, which potentially determined natural ingredients comparable to SAW Palmetto within the treatment of male model (androgenetic alopecia or aga), although Some first findings Specify potential guarantees. Prescription DHT shampoos comparable to Ketoconazole have been proven in studies Treat hair loss and androgenetic alopecia effectivelyEspecially when the condition was treated aggressively and persistently with the shampoo.

Prescription DHT shampoos comparable to ketoconazole were also shown Work simpler in the event that they are taken with an oral drug This lowers the DHT levels comparable to finasteride, a 5A reductase inhibitor that blocks the enzyme, converts the testosterone into DHT. There are some restrictions on the treatment of hair loss with DHT shampoos. As with other DHT-low medication, the results of those shampoos only last so long as they use them. If prescription shampoos are stopped, the symptoms return. While DHT shampoos are in a position to arouse energetic hair follicles which might be somewhat resting, follicles which might be already inactive are usually not affected.

Do DHT shampoos have unwanted effects?

Most DHT shampoos comparable to Ketoconazole have minimal unwanted effects. You can contain the next:

• Bubbles
• Change of text on the hair
• Itchy skin
• Skin irritation
• Skin dryness

If you may have more serious unwanted effects after using DHT shampoo comparable to hives or respiratory respiratory, you might have an allergic response and may search for immediate medical care.

Who is a perfect candidate for DHT shampoos?

Men and ladies who’re in search of treatment for a scalp flag infection or dandruff may be helpful. DHT shampoos may be utilized by men and ladies to treat hair loss by androgenetic alopecia or telogen -fleuvium. Since DHT shampoos serve to forestall hair loss and possibly rejuvenate follicle and never reverse the hair loss that has already occurred, those in the sooner stages of hair loss are ideal candidates. Men who take oral hormone recipes for hair loss, comparable to finasteride, Can also use a DHT shampoo Like ketoconazole as a mix therapy.

Originally published: March 3, 2025 at 11:06 a.m. PST

By Tom Murphy, AP Health Writer

Deliveries of obese treatments with high demand improveBut that doesn't mean it is simpler to get them.

Many employers and insurers scale the reporting on wide and zepbound and a crucial government program, Medicare, don’t cover the medication for obesity. In the meantime, there are some large employers of canopy, but their commitment will not be guaranteed.

Treatment prices that may overdo lots of of dollars every month, many individuals make it difficult to afford these medication. This could make the life -changing weight reduction that the patients rely on the quilt they’ve and the way long it takes.

Cover complications are usually not unusual within the US health system. However, the challenge is enlarged for these obesity treatments, since a broad swath of the population might be justified to take themAnd patients need to stay on the medication to maintain the burden.

“There are currently many people who want access to the medication and cannot get it,” said Katherine Hempstead, Senior Policy Consultant at Robert Wood Johnson Foundation.

The cover varies depending on the payment of the invoice

Paul Mack fell about £ 70 after starting Wegovy. The Redwood City, California, said that food noises – constant thoughts of the food – faded, and he was in a position to have a heart procedure.

The treatment was covered by the Californian Medicaid program Medi-Cal. Then the 50-year-old security guard got a rise. From last summer he has not qualified for Medi-Cal for several months and lost reporting on the medication.

He achieved two pants sizes.

“I couldn't control the food,” he said. “The whole sound came back.”

The reporting on these medication stays greater than a 12 months after Zepbound's entry to challenge Wegovy.

The profit consultant Mercer says that 44% of US corporations covered obesity medication with 500 or more employees last 12 months. It is much more common for larger employers.

More than a dozen MedicAID programs for individuals with low incomes also cover more obstacle.

But only a number of insurers cover the medication on individual insurance marketplaces. And some plans limit your reporting with things like inquiries after prior approval or preliminary approval.

The lack of a medical cover also stays an issue, especially for individuals who retire and switch to the state-funded program in the quilt sponsored by the employer.

“The patients come to us to switch to Medicare and lose the cover,” said Dr. Katherine Saunders, expert for obesity at Weill Cornell Medicine and co -founder of the obesity -treatment company FlyteHealth. “We talk about backup plans a year before the transition.”

Costs and unsure payments than the payer concerns

In independence from Philadelphia-Denependence Blue Cross, the drugs have only reduced reporting on medication for some customers from this 12 months. Corporate officials say that the insurer who is worried about premium hikes would need to impose all customers on when this continues.

The costs were also a consider decisions of West Virginia And North Carolina Civil servants to finish similar programs that cover the state employees.

Vanderbilt University researcher Stacie Dusetzina ask these concerns about how long employers who’ve added reporting now not cared for sharply.

“That will probably address the expenses,” said Dusetzina, a professor of health policy, who examines drug costs.

Drug manufacturers advertise the savings that these medication can achieve by improving the health of patients and warding off future serious illnesses resembling heart attacks or strokes.

However, experts within the healthcare sector find that there are not any guarantees that the employer or insurer who covers the medication will finally use these benefits because people can change jobs or insurers.

Will reporting ever change into consistent?

There isn’t any clear approach to widespread reporting on these drugs for obesity, even when surveys show Americans prefer Medicaid and Medicare cover the prices.

The leaders of the Zepbound manufacturer Eli Lilly have seen how the reporting for his or her drug has grown steadily, and so they are optimistic that they may proceed.

The administration of former President Joe Biden A rule proposed That would enable Medicare and a wider medicaid cover. Fate remains to be uncertain in the federal government of President Donald Trump.

A legislative template during which Medicare reports can be found has been in congress within the congress for years. But it will not be planned.

The drug manufacturers are currently testing several additional obese treatments. Such a possible competition could reduce prices and arrange more cover.

Gap -sized cover complicated the treatment plans

Dr. Amy Rothberg says that the dearth of consistent reporting in conflict about writing recipes stays because she will not be sure how long patients can take the medication.

“We know from the studies that people go out of these medicationShe regains her weight, ”said Rothberg, director of the Weight Management Program of the University of Michigan. “I don't want to do any damage.”

Some insurers need dietary and sports changes for the patient before covering a weight reduction medication. These changes should occur in reference to the establishment of drugs, said Dr. Lydia Alexander, President of the Obesity Medicine Association.

It has also seen requirements for a body mass index of 40 or more that corresponds to severe obesity before the quilt can begin.

“We say that obesity is an illness, but we don't treat them like an illness,” she said.

Originally published: February 25, 2025 at 11:17 a.m. PST

Shares of Hims & Hers Health 22% closed on Tuesday, the day after the Telemealth Company published the outcomes of the fourth quarter, which was upset by the gross margin and triggered concerns concerning the way forward for its weight reduction transaction.

HIMS & HER has achieved sales of $ 481 million for the quarter, which rose to a rise of 95% in comparison with USD August 246 million in the identical period last yr. The net profit rose to $ 26.01 million or 11 cents per share of USD 1.25 million or 1 cents per share within the previous yr.

The company's gross margin or the profit that was left behind after taking the prices of the products sold was 77%, disappointing analysts, which, in line with StreetCcount, expected 78.4%.

In the quarterly call of the corporate with investors on Monday, Yemi Okupe Chief Financial Officer said the scaling of the GLP 1 offer of the corporate and its strategic price options are in charge.

Hims & Her In May the tightened Semaglutide began, the lively ingredient in Novo Nordisks GLP-1 weight reduction medication Ozempic and Wegovy. Compiled medication might be produced when brand treatments are in systems ShortageBut the US Food and Drug Administration announced on Friday that the shortage of Semaglutide injection products was solved.

As a result, Hims & Hus said on Monday that after the primary quarter it should probably stop to supply Semaglutid on his platform, although some consumers may proceed to find a way to access personalized cans in the event that they are clinically applicable. The GLP-1 offer generated sales of greater than $ 225 million for the corporate in 2024.

“We have to notify customers in the coming one or two months that they have to look for alternative options for commercial doses,” said Andrew Dudum, CEO from HIMS & HERS, when calling.

In the longer term, the corporate said that its weight reduction offer will mainly consist of its oral drugs and the injectable drug Liraglutid, which it desires to introduce on its platform this yr.

Morgan Stanley analysts said on Tuesday in a sign that the corporate's report was “a lot to digest”. They kept their same weight rating for the share and said they were surprised by the extent of the corporate's instructions in 2025.

HIMS & HERS expects sales of two.3 billion US dollars and a couple of.4 billion US dollars this yr. The company added that it could expect its weight reduction offer to generate not less than 725 million US dollars, except contributions from Compound Semaglutid.

“We remain positive about the long-term opportunities and underline the attractive platform of the company and the solid track record that you differentiate between digital health and DTC compenses,” said Morgan Stanley's analysts.

The analysts of the Bank of America said that the corporate could have some success within the transition from patients to its other weight reduction offerings reminiscent of its oral medication, nevertheless it increases with a “considerable explanation risk” with increasing supply of name names.

In addition, the analysts said that the competitors of HIMS & HERS are probably moving the marketing dollar to other products reminiscent of erectile dysfunction and hair loss, which could put pressure on promoting costs. They repeated their underperform -Rating for the share.

“Overall, we do not see the sales advice from 2025 on our head and think that the Beat and considerable story is likely to be over at short notice,” wrote the analysts of the Bank of America in a message on Tuesday.

Citi -analysts have now said that it was “exhausting” to “exhausting” the handbook of HIMS & HERS, since it could require a “considerable acceleration” when using its other weight reduction products. They said they were less confident concerning the success of those offers.

Nevertheless, the analysts increased their price goal for $ 25 to $ 27.

“We are waiting for a more convincing starting point and further details on growth points EX-GLP-1S before we become more constructive,” they wrote in a Monday note.

Zepbound, Mounjaro Performance

As governor Gavin Newsom, certainly one of his regular times in regards to the superiority of California in comparison with other countries-especially those with conservative politics comparable to Texas and Florida, he omits comfortable features which might be lower than admirable. The exclusions include Californian levels of California PovertyPresent homelessnessPresent Unemployment, Pension calculations And Housing costs These are the best or near the nation.

One of the strong – and most vital – disappointments of California is the consistent failure of helping elementary and middle school students to realize higher national test ends in fundamental educational skills comparable to reading and arithmetic.

Simply put, the Californian education system will not be only behind most other states, but in addition for many who consider Newsom and other Californians to be culturally backwards. In addition, California schools haven’t yet recovered from the lack of education that were suffered during Covid 19 pandemic.

This hard reality is unveiled by the federal government within the recent round of educational tests National assessment of the progress of education. The data is extensive and severely analyzed, but EdSource, a non -profit news agency that’s dedicated to the recording of California Education Trends, Fortunately, it did for the remainder of us.

“The latest results usually show no progress,” said Edsource last week. “The results in the fourth and eighth grade fell again, so California left 9 points and the nation 8 points under 2017. Math was mixed – in fourth grade, but not enough to catch in 2019, the eighth class another dip fell. “

EdSource also found that the common rankings “Mask, the differences between the highest and powerful students expand. In the fourth grade reading, the students fell by 1 point in the 90th percentile between 2019 and 2024, and the scores in the 75th percentile fell by 3 points. However, the results for students in the 10th percentile fell by 10 points, and for students in the 25th percentile they fell by 8 points. “

High-warts low reading and math skills in primary school and middle school students are particularly worrying, since these are tools that have to be mastered in order to successfully navigate the university and post-graduation college courses or vocational training. The faculties have an impact not only on the chances of the students to become successful adults, but also the needs of the state for one educated workforce and entitled to vote.

Current data underline this negative effect. While California has a huge homeless population and more than a million members of its working population are unemployed, employers also find it Very difficult to fill job offers with employees that are either sent or can be trained.

This is not a new problem. California has stayed behind other countries for decades and has a chronic “performance gap” between poor or English learning students and that from privileged circumstances.

More than a decade ago, at that time, GOV. Jerry Brown and the legislator overtook school financing in order to provide schools with additional funds with a large number of students. While countless billions of dollars were redirected The results have only improved fractionally at best.

Money is certainly a factor for the quality of the lessons. The state has increased the expenses for schools in recent years and would have almost 25,000 US dollars per student in Newsoms proposed budget 2025-26. Newsom has promoted additional state aid for kindergarten and pre -children. The state now offers universally free lunch and has implemented early screening to recognize reading deficiencies.

These are potentially positive steps to close performance gaps, but money is not the only factor. Edsorce notes that “some states whose points within the reading of the fourth grade, including Mississippi, Connecticut and Colorado, California, have taken over extensive reading plans based on the science of reading.”

This is the current term for Phonics, the California's educational institutions Has often resisted Despite a number of prove that it improves the flexibility of the kids to read.

Just a few years ago, a little-known drug called Ozempic – previously used only to treat diabetes – emerged as a promising recent drug for weight management.

The Food and Drug Administration of the Administrative Agency Approval of Ozempic in 2021 for weight reduction treatment ushered in a brand new era for the category of medication that was called Glucagon-like peptide-1 agonistsor GLP-1.

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have turn into household names and key tools within the fight against obesity: 1 in 8 American adults Say they used a GLP-1 drug, and projections show that by 2030, 1 in 10 Americans are more likely to with these medications.

Research from my lab and others now suggests that GLP-1 drugs could also treat dozens of other ailments, including cognitive problems and addiction problems. However, my colleagues and I also found previously unidentified risks.

I’m a Physician Scientist And I lead a clinical epidemiology center that addresses essentially the most pressing public health issues. My team is working to handle critical knowledge gaps about Covid-19, Long Covid, influenza, vaccines, effectiveness and risks of common medicines, and way more.

On January 20, 2025, my team published a study of greater than 2.4 million individuals who evaluated the risks and advantages of GLP-1 drugs over 175 possible health outcomes. We found that these drugs reduced the danger of 42 health outcomes, nearly 1 / 4 of the entire we analyzed. These include neurocognitive disorders similar to Alzheimer's disease and dementia, substance use and addiction disorders, coagulation disorders, and a number of other other medical conditions.

Unfortunately, we also found that GLP-1 drugs carry significant unwanted side effects and increase the danger of 19 health conditions we studied, similar to: B. Gastrointestinal problems, kidney stones and Acute pancreatitisthrough which the pancreas becomes inflamed and dysfunctional.

https://www.youtube.com/watch?v=npyvr_2_rj4

Cognitive advantages

One of the important thing health advantages was that the GLP-1 drugs reduced the danger of neurodegenerative disorders, including Alzheimer's disease and dementia. These results are consistent with other research, including evidence from preclinical studies, showing that these drugs may reduce inflammation within the brain and improve the brain's ability to form and strengthen connections between its cells, thereby improving the way in which how they convey with one another. These effects help reduce cognitive decline.

Two other key studies have shown Patients treated with a GLP-1 drug for diabetes had a lower risk of dementia.

All of those studies strongly suggest a possible therapeutic use of GLP-1 drugs within the treatment of cognitive decline. Ongoing randomized trials—the gold standard for evaluating recent drug uses—are examining the results of GLP-1 drugs in early Alzheimer's disease, with results expected later in 2025.

Curb addiction and suicidal thoughts

GLP-1 medications have also shown potential for reducing the risks of several substance use disorders similar to alcoholPresent tobaccoCannabis, opioids and stimulants. This could also be attributable to the flexibility of those medications to modulate reward pathways, impulse control, and inflammatory processes within the brain.

The effectiveness of GLP-1 drugs in curbing addictive behavior may explain their spectacular success in treating obesity, a chronic disease state that many have suggested is actually a food addiction disorder.

Our study showed a reduced risk of suicidal ideation and self-harm in people using GLP-1 medication. This finding is especially significant Previous reports of suicidal thoughts and self-harm In people using GLP-1 drugs. In response to those reports, the European Medicines Agency conducted a review of all available data and concluded that it existed No evidence of an increased risk of suicide In people using GLP-1 drugs.

Now at the least two studies, including our own, show that GLP-1 drugs actually do Reduce the danger of suicide.

Other advantages

In addition to the well-documented effects of GLP-1 drugs in reducing the risks of undesirable cardiovascular And Kidney resultsOur study shows a major effect on reducing the danger of blood clotting, deep vein thrombosis and pulmonary embolism.

A puzzling finding in our study is the reduced risk of infectious diseases similar to pneumonia and sepsis. Our data complement one other recent study that reached an analogous conclusion cardiovascular death and death from infectious causesespecially Covid-19.

This is especially vital as Covid-19 is taken into account to be significant cardiovascular risk factor. Whether GLP-1 drugs fully offset the increased risk of heart problems related to CoVID-19 must be thoroughly evaluated.

GLP-1 drugs might also be useful in Fatty liver disease treatment and conditions from asthma to chronic obstructive pulmonary diseasesleep apnea, OsteoarthritisDepression and eye disorders.

https://www.youtube.com/watch?v=sygijtbx2xs

Risks and challenges

Despite their broad therapeutic potential, GLP-1 drugs will not be without risks.

Gastrointestinal problems similar to nausea, vomiting, constipation and constipation and gastroesophageal reflux disease are amongst essentially the most common opposed effects related to GLP-1 drugs.

Our study also identified other risks, including low blood pressure, sleep problems, headaches, kidney stone formation, and Gallbladder disease and diseases related to the bile ducts. We also saw an increased risk of drug-induced inflammation of the kidneys and pancreas – each serious conditions that may result in long-term health problems. These results highlight the importance of careful monitoring in people taking GLP-1 drugs.

A big challenge in the usage of GLP-1 drugs is the high rates at which patients stop usingoften driven by their exorbitant costs or the occurrence of opposed effects. Stopping can result in rapid weight gain.

This is an issue because obesity is a chronic disease. GLP-1 drugs provide effective treatment but don’t address the underlying causes of obesity and metabolic dysfunction. As a result, GLP-1 drugs should be taken long-term to take care of their effectiveness and stop rebound weight gain.

In addition, many questions remain concerning the long-term effectiveness and risks of those drugs, in addition to whether there are differences between GLP-1 formulations. Answering these questions is critical to guiding clinical practice.